First line Immunotherapy for Non-Small Cell Lung Cancer

Immunotherapy for non-small cell lung cancer (NSCLC) is incorporated increasingly in first line treatments protocols. Multiple phase 3 studies have tested different medications targeting programmed death receptor 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasser, Nicola J., Gorenberg, Miguel, Agbarya, Abed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695295/
https://www.ncbi.nlm.nih.gov/pubmed/33171686
http://dx.doi.org/10.3390/ph13110373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695295/
https://www.ncbi.nlm.nih.gov/pubmed/33171686
http://dx.doi.org/10.3390/ph13110373

Ejemplares similares